Immunization with peptide P10, derived from gp43, and chemotherapy were used together in an attempt to improve treatment of paracoccidioidomycosis and prevent relapses. The combined treatment showed an additive protective effect when administered at 48 h or 30 days after intratracheal challenge. Its use is recommended to improve regular chemotherapy and reduce the duration of treatment.
a Boldface indicates a predominat Th-1 or Th-2-like response according to the cytokines produced (IL-12/IFN-␥ or IL-4/IL-10, respectively). *, statistically significant difference (P Ͻ 0.05) relative to mice treated only with the drug; #, statistically significant difference (P Ͻ 0.05) relative to mice immunized with P10 and treated with the drug. Values are means Ϯ standard deviations of measurements from 5 to 10 animals in each group. The whole experiment was repeated twice with reproducible results. V, liver. * , significant differences between the combined treatment and both P10 vaccine alone and drug treatment alone (P Ͻ 0.05).
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on July 10, 2017 by guest http://aac.asm.org/ and 14 groups (n ϭ 10 each) of BALB/c mice (male, 6 to 8 weeks old) in each protocol. Controls included a group infected with Pb18 only, another group infected and immunized with P10, and a group infected and treated with Freund's adjuvant. Five groups of mice were infected and treated with a single antifungal drug: fluconazole (Pfizer), ketoconazole (Janssen-Cilag), itraconazole (Janssen-Cilag), amphotericin B (Fungizone; Bristol Mayers Squibb), sulfamethoxazole (Sigma, St. Louis, MO), or trimethoprim-sulfamethoxazole (Bac-sulfitrin; Ducto). An additional five groups were treated with antifungal drugs combined with P10 immunization. Drug treatment in the first and second protocols was started after 48 h and 30 days, respectively, after intratracheal infection with 3 ϫ 10 5 yeast cells (10) . The treatment was continued for 30 days, during which groups of mice received intraperitoneal doses of itraconazole (10 mg/kg), fluconazole (10 mg/kg), ketoconazole (8 mg/kg), sulfamethoxazole (15 mg/kg), or trimethoprim-sulfamethoxazole (3 and 15 mg/kg, respectively) every 24 h. Amphotericin B (1.5 mg/kg) was administered every 48 h. Immunization was carried out weekly for 4 weeks with 20 g of P10 in complete Freund's adjuvant (CFA) once and in incomplete Freund's adjuvant (IFA) three times.
Analysis of CFU in organs was carried out after 30 and 90 days of infection under protocol 1. The pattern of CFU in organs showed a significant reduction of fungi recovered from animals either immunized only or treated with antifungal drugs. An additive protective effect of P10 and antifungal drugs was observed. In the group of mice treated with sulfamethoxazole, an early protection was followed by relapse, although the group with associated sulfamethoxazole and P10 vaccination succeeded in controlling the disease (Fig. 1) . The combination of drugs and P10 led to increased protection as FIG. 3 . Additive effect of P10 immunization and trimethoprim-sulfamethoxazole treatment, after 120 days, in mice intratracheally infected under protocol 2 (treatment after 30 days of infection). (A) Lung section from untreated mouse; (B) lung section from mouse immunized with P10; (C) lung section from mouse treated with trimethoprim-sulfamethoxazole; (D) apparently resolved granulomas, with very few fungal cells, in lung section of mouse subjected to P10 immunization and drug treatment. Three hundred microscopic fields for all four groups were analyzed, with the following results: group A, granulomas with yeasts, 24%, and noninflamed areas, 27%; group B, granulomas with yeasts, 15%, and noninflamed areas, 46%; group C, granulomas with yeasts, 32%, and noninflamed areas, 26%; group D, granulomas with yeasts, 12%, and noninflamed areas, 55%. Statistically significant differences (P Ͻ 0.05) were observed for P10-treated groups. Gomori silver staining was used; magnification, ϫ25.
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NOTES 2817 on July 10, 2017 by guest http://aac.asm.org/ reflected in organ histological areas with very few or undetectable yeast cells. With protocol 2, we aimed at reproducing the situation of established infection. The fungal burden was examined after 60 and 120 days of infection. The pattern of CFU in organs showed an additive effect of P10 immunization and drug treatment at 60 and 120 days after infection, with 60 to 80% reduction of lung CFU compared with controls (untreated infected animals or those that received only CFA). P10 immunization or chemotherapy separately achieved 40 to 60% reduction of CFU; administration of P10 together with the drug fully controlled the "relapsing" effect (Fig. 2) . Histopathology showed large preserved areas in the lung and very few yeast cells. In Fig. 3 (protocol 2) , we show the lung histopathology of a mouse treated with sulfa-derived drugs alone and combined with P10 vaccination. Clearly, P10 vaccination was the essential adjuvant therapy to contain the infection.
P10 activates a Th-1 immune response with a known pattern of cytokine production in vitro and in vivo (10) . First, we studied the cytokine levels in the lungs of mice after 48 h of infection. Even though a few results were not statistically significant, a pattern was clearly defined. At 30 days no changes in cytokine levels were observed in drug-treated groups of mice in combination or not with P10. After 90 days, however, there was a consistent decrease of interleukin-4 (IL-4) and IL-10 and an increase of gamma interferon (IFN-␥) in drug-treated animals also immunized with P10 in relation to mice treated with drugs only (Table 1) . In relation to controls, no differences were seen between sham infection and the group that received only adjuvant. Animals that were only infected or only immunized with P10 showed increased levels of both type 1 and type 2 cytokines (Table 1) .
In animals with established infection, sham-and adjuvanttreated groups of mice did not show differences, whereas the group infected with P. brasiliensis but untreated showed increased production of IL-4, IL-10, IL-12, and IFN-␥. P10 immunization promoted even higher levels of IL-12 and IFN-␥ but decreased concentrations of IL-4 and IL-10. Drug treatment generally stimulated IL-4 and IL-10 cytokines compared to the case for the untreated infected group. The combination with P10 immunization showed, in general, increased production of IL-12 and IFN-␥ and reduction of IL-4 and IL-10, with little exception (Table 2) . Thus, although both Th-1 and Th-2 cellular immune responses were present in all cases, drug treatment either had little influence or caused an increase in the Th-2 response, possibly correlated with increased destruction of fungal cells. The least effective chemotherapy, with trimethoprim-sulfamethoxazole, which allowed a late relapsing infection, doubled the production of IL-4 and IL-10 and had little effect on IL-12 and IFN-␥. Association with P10 greatly stimulated a Th-1 response with increased production of IL-12 and IFN-␥, clearly leading to protection. Several features have been examined for validation of P10 as a candidate vaccine, including (i) the presentation of P10 by different mouse haplotypes (10); (ii) conservation in nature, determined by examining gp43 molecules from different isolates (1); (iii) immunogenicity in constructions that do not require complete Freund's adjuvant (6, 11) ; (iv) presentation by a large number of human HLA-DR molecules, more than that for other promiscuous peptides derived from gp43 (2); and (v) its role in the immunoprotection of mice infected with P. brasiliensis and subjected to chemotherapy, which was the focus of the present work. The data obtained strongly suggest that a P10-based vaccine should be used to improve chemotherapy, reduce treatment time, and prevent relapsing disease. Boldface indicates a predominat Th-1 or Th-2-like response according to the cytokines produced (IL-12/IFN-␥ or IL-4/IL-10, respectively). *, statistically significant difference (P Ͻ 0.05) relative to mice treated only with the drug; #, statistically significant difference (P Ͻ 0.05) relative to mice immunized with P10 and treated with the drug. Values are means Ϯ standard deviations of measurements from 5 to 10 animals in each group. The whole experiment was repeated twice with reproducible results.
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